An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14).

Chen, Ming-HuangMing-HuangChenChou, Wen-ChiWen-ChiChouHsiao, Chin-FuChin-FuHsiaoLiu, Yi-ChangYi-ChangLiuHsu, ChiunChiunHsuYanshen, ShanShanYanshenHung, Yi-PingYi-PingHungHsieh, Chia-HsunChia-HsunHsiehChiu, Chao-HuaChao-HuaChiuLiu, Ta-ChihTa-ChihLiuCho, Shih-FengShih-FengChoLiu, Tsang-WuTsang-WuLiuChao, YeeYeeChaoYI-PING HUNG2020-06-112020-06-1120190732-183Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/500499An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14).journal article10.1200/JCO.2019.37.15_suppl.4101WOS:000487345805288